Welcome to our dedicated page for Envoy Medical news (Ticker: COCH), a resource for investors and traders seeking the latest updates and insights on Envoy Medical stock.
Envoy Medical, Inc. develops hearing-health technologies focused on fully implanted hearing solutions. The company’s portfolio includes the Esteem FI-AMEI, an FDA-approved fully implanted active middle ear implant for adults with moderate to severe sensorineural hearing loss, and the investigational Acclaim cochlear implant, which uses a sensor designed to work with the ear’s natural anatomy rather than an external microphone.
Recurring company news covers Acclaim clinical-study updates, FDA-related development toward a Premarket Approval pathway, financial results, capital-structure actions, Nasdaq listing compliance, board and governance changes, and intellectual-property updates tied to its hearing segment.
Envoy Medical (NASDAQ: COCH) announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,465,754 on November 11, 2025 for a "Combination Implant System with Removable Earplug Sensor and Implanted Battery."
The patent covers an implantable stimulator with rechargeable energy storage paired with a removable earplug that receives power, contains a sensor and signal processor, and transmits stimulation signals to the implant. Envoy says the patent expands its intellectual property around fully implanted cochlear technology and complements progress in its pivotal Acclaim cochlear implant clinical trial. The Acclaim device holds FDA Breakthrough Device Designation (2019) and is under investigation in a U.S. pivotal trial.
Envoy Medical (NASDAQ: COCH) announced on November 18, 2025 that the first 10 patients in the pivotal Acclaim fully implanted cochlear implant trial completed their six-month follow-up visits with no serious adverse events reported.
The update notes recent trial expansion, accelerating enrollment, new patent issuances, and that Acclaim holds FDA Breakthrough Device designation (2019). The device remains investigational and is being evaluated in a U.S. pivotal trial ahead of a planned FDA submission and potential commercialization.
Envoy Medical (NASDAQ: COCH) reported a transformational Q3 2025 and subsequent events on November 10, 2025. Key corporate actions included extinguishing $32 million of debt, expanding its patent portfolio with multiple new issuances, and reaching clinical three-month follow-up milestones.
Subsequent to quarter end the company received FDA approval to expand its pivotal trial to the final stage, enrolled the first three patients in that stage, and announced closing of a registered direct offering for up to $16 million. Q3 net revenue was $42,000 and cash was approximately $3.556 million as of September 30, 2025.
Envoy Medical (NASDAQ: COCH) announced on November 4, 2025 that the first three patients have been enrolled and implanted in the final stage of the pivotal U.S. trial for the fully implanted Acclaim cochlear implant. Those initial surgeries were performed at two of seven U.S. investigational sites.
The final stage will implant 46 patients in total; 43 spots remain. The Acclaim device, engineered to operate without external wearable components, received FDA Breakthrough Device Designation in 2019 and remains under investigation. Management said faster enrollment supports progress toward FDA submission and potential commercialization.
Envoy Medical (NASDAQ: COCH) marked the three-year anniversary of the first fully implanted cochlear implant, first implanted on October 24, 2022. The company noted positive patient reports from three Early Feasibility Study (EFS) participants and said all three surpass three years post‑implant.
Envoy said it received FDA permission to expand its pivotal clinical trial into the second and final stage and holds a Breakthrough Device Designation. The pivotal Acclaim cochlear implant study is enrolling at multiple U.S. sites, and Envoy emphasizes U.S.‑based headquarters and manufacturing.
Envoy Medical (NASDAQ: COCH) received a positive listing determination from the Nasdaq Hearings Panel on October 27, 2025, allowing continued listing while the company addresses compliance with Nasdaq Listing Rule 5550(b)(2).
The Panel cited Envoy Medical's recent equity capital raises and debt extinguishment, which together substantially increased stockholders' equity, and the FDA's approval to advance the fully implanted Acclaim cochlear implant clinical trial to its final stage. The company noted over 28 million shares outstanding and higher trading volume since the trial expansion announcement.
The Panel set a compliance deadline of February 23, 2026; Envoy Medical said it will provide timely updates on progress.
Envoy Medical (NASDAQ: COCH) closed a registered direct offering on October 9, 2025, selling 3,007,524 Class A shares at $1.33 per share for gross proceeds of approximately $4.0 million before fees. In a concurrent private placement, Envoy issued unregistered warrants to purchase up to 9,022,572 Class A shares at an exercise price of $1.33 per share; those warrants are exercisable immediately and expire 24 months after the registration statement effective date. H.C. Wainwright acted as exclusive placement agent. Net proceeds are intended for working capital and general corporate purposes. The company cautioned there is no assurance the warrants will be exercised for cash.
Envoy Medical (NASDAQ: COCH) announced a registered direct offering of 3,007,524 shares at $1.33 per share to raise approximately $4.0 million in gross proceeds, and a concurrent private placement of unregistered warrants to purchase up to 9,022,572 shares at an exercise price of $1.33. The warrants are exercisable immediately and expire 24 months after the registration statement effective date. The offering is expected to close on or about October 9, 2025, with H.C. Wainwright serving as placement agent. Net proceeds are intended for working capital and general corporate purposes.
Envoy Medical (NASDAQ: COCH) received FDA approval on October 7, 2025 to expand its pivotal trial for the fully implanted Acclaim cochlear implant to the final stage based on promising three-month data from the first 10 patients.
All 10 participants reached the three-month milestone with no serious adverse events or unanticipated device effects. The company now expects full enrollment by early 2026, has moved timelines up 3–6 months, and reduced anticipated capital needs by $10–$15 million.
Envoy Medical (NASDAQ:COCH), a hearing health company specializing in fully implanted hearing solutions, has announced its participation in the upcoming American Academy of Otolaryngology Head and Neck Surgery (AAO-HNSF) conference. The event will take place on October 11th-14th, 2025 in Indianapolis, IN.
During the conference, the company will conduct individual meetings with implanting surgeons at booth #1108 to discuss recent product developments. Interested attendees can schedule meetings via info@envoymedical.com.